Dysregulated activation of the innate immune system underlies multiple significant medical problems, including our focus areas in chronic pain, dementia, and opioid use disorders. Our latest advances deliver receptor-active peptides (“RAPs”) that re-balance several chemokine receptor systems from a neurodegenerative state to one of neuroregeneration. CPB’s research platform consists of small safe oral peptides, suitable for 1x daily dosing, that are biased antagonists of select chemokine receptors, such as CCR2/CCR5, as treatments in pain and neurodegeneration. We believe that balancing chemokine receptor activation in the brain provides several validated treatment opportunities. Our focused indications are in neuropathic and other chronic pain conditions, with development of uses in Parkinson’s Disease and Opioid Use Disorders.
